Category - Markets

Markets

Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast caner

Stifel upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) to “buy” from “hold” and raised its price target to $7 from $1.30, saying the “zotatifin combo is emerging as an active and underappreciated asset in breast cancer.”...

May 26, 2023

Markets

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...

May 22, 2023

Markets

Cantor starts Acumen Pharma at OW; PT $13

Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with an “overweight” rating and 12-month price target of $13. The stock closed at $5.45 on May 17. Acumen is a neuro-Innovator leveraging its...

May 19, 2023

Markets

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Raymond James upgraded Eupraxia Pharmaceuticals (TSX:EPRX) to “strong buy” from “outperform” and maintained its price target of $11 (Canadian). The stock was quoted at $6.99, up 15 cents at midday on May 18. Pointing to...

May 18, 2023

Markets

BTIG starts Coya Therapeutics at buy; PT $15

BTIG launched coverage of Coya Therapeutics (NASDAQ:COYA) with a “buy” rating and a $15 price target. The stock closed at $5.76 on May 17. Analyst Thomas Shrader, Ph.D., writes that his price target is based on “our...

May 18, 2023

Markets

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

Cantor Fitzgerald raised its price target for Hepion Pharmaceuticals (NASDAQ:HEPA) to $28 after a one-for-20 reverse stock split on May 10, and maintained an “overweight” rating. The stock closed at $6.81 on Friday. “We...

May 15, 2023

Markets

BTIG cuts Babylon Health on earnings, cash, go-private transaction

BTIG downgraded Babylon Health (NASDAQ:BBLN) to “sell” from “neutral” with a price target of zero, reflecting concerns around earnings, cash flow and cash needs, and the structure of a possible go-private transaction...

May 11, 2023

Markets

BTIG cuts CareDx to hold on CMS policy changes; removal of guidance

BTIG downgraded CareDx (NASDAQ:CDNA) to “neutral” from “buy” and removed its price target. The stock closed at $8.59 on May 10. CareDx is a market leader in blood-based testing for both heart and kidney transplant...

May 11, 2023

Markets

Research Capital bullish on Theralase bladder cancer data

Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) data generated to date shows that Ruvidar’s efficacy is “strong and durable” for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and...

May 10, 2023

Markets

Dawson James ups Can-Fite to buy on valuation call

Dawson James upgraded Can-Fite BioPharma (NYSE American, TASE:CANF) to “buy” from “neutral” with a $6 price target. The stock closed at $1.74 on April 28. Analyst Jason Kolbert writes that the stock is reaching new lows...

May 1, 2023

Category - Markets

Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast caner

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Cantor starts Acumen Pharma at OW; PT $13

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

BTIG starts Coya Therapeutics at buy; PT $15

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

BTIG cuts Babylon Health on earnings, cash, go-private transaction

BTIG cuts CareDx to hold on CMS policy changes; removal of guidance

Research Capital bullish on Theralase bladder cancer data

Dawson James ups Can-Fite to buy on valuation call

General

More